ALPHA TAU ANNOUNCES ACCEPTANCE INTO FDA’S TOTAL PRODUCT LIFE CYCLE ADVISORY PROGRAM TO ACCELERATE MARKET ACCESS TO ALPHA DART® FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Reuters · 10/21 12:30

Please log in to view news